+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Unpredictability of flecainide plasma concentrations in patients with renal failure: relationship to side effects and sudden death?



Unpredictability of flecainide plasma concentrations in patients with renal failure: relationship to side effects and sudden death?



Therapeutic Drug Monitoring 16(4): 349-351



We report a retrospective evaluation of plasma concentrations of flecainide obtained from five dialysis patients during chronic oral treatment. A more than sevenfold variation in the dose/concentration relationship was observed. Plasma concentrations of flecainide above 1,200 ng/ml appeared to be associated with serious side effects and in one case with sudden death. Therefore, flecainide should be used with extreme caution in patients with impaired renal function. Frequent therapeutic drug monitoring should be mandatory.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 009696729

Download citation: RISBibTeXText

PMID: 7974623


Related references

Unpredictability of Flecainide Plasma Concentrations in Patients with Renal Failure. Therapeutic Drug Monitoring 16(4): 349-351, 1994

Relationship of plasma concentrations of human atrial natriuretic peptide to renal function and blood pressure in patients with progressive chronic renal failure. Klinische Wochenschrift 65(Suppl. 8): 127-132, 1987

Relationship between plasma concentrations and suppression of ventricular extrasystoles by flecainide acetate (R-818), a new antiarrhythmic, in patients. Arzneimittel-Forschung 32(2): 155-159, 1982

Plasma free thyroxine (FT4) concentrations during hemodialysis in patients with chronic renal failure: effects of plasma non-esterified fatty acids on FT4 measurement. Endocrine Journal 43(5): 487-493, 1996

Mechanism of death in patients with congestive cardiac failure: the change in plasma norepinephrine and its relation to sudden death. Cardioscience 1(1): 29-32, 1990

Plasma adiponectin concentrations in patients with chronic renal failure: relationship with metabolic risk factors and ischemic heart disease. Hormone and Metabolic Research 36(10): 721-727, 2004

Death following return to dialysis in patients with failed renal transplants Relationship to age, gender and plasma glucose level at the time of graft failure. Journal of the American Society of Nephrology 10(PROGRAM AND ABSTR ISSUE): 762A, 1999

Relationship between mycophenolate mofetil side effects and mycophenolic acid plasma trough levels in renal transplant patients. Arzneimittel-Forschung 50(10): 936-940, 2000

How to reduce sudden cardiac death in patients with renal failure. Heart 98(4): 335-341, 2012

Elevated plasma flecainide concentrations in heart failure. Deutsche Medizinische Wochenschrift 112(44): 1698-1700, 1987

Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. Journal of the American Heart Association 1(5): E000760, 2012

Republished: How to reduce sudden cardiac death in patients with renal failure. Postgraduate Medical Journal 88(1041): 418-424, 2012

Risk of sudden death in patients with chronic renal failure and hemodialysis. Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 108(2): 290-295, 2005

Cardiac side effects and sudden death in hospitalized psychiatric patients. Diseases of the Nervous System 38(2): 69-72, 1977

Sudden death an unappreciated manifestation of cardiac amyloidosis analysis of 6 necropsy patients with sudden death without preceding congestive heart failure. Laboratory Investigation 46(1): 87A, 1982